Higher microRNA-221 and lower microRNA-451 expression are associated with poor prognosis in patients with thyroid papillary carcinoma
##plugins.pubIds.doi.readerDisplayName##:
https://doi.org/10.23938/ASSN.1086Gako-hitzak:
microRNA-451, microRNA-221, Thyroid papillary carcinoma, Pathological features, PrognosisLaburpena
Background. To analyze the relationship between serum microRNA-221 and microRNA-451 expression and the pathological features and prognosis of patients with thyroid papillary carcinoma.
Methods. Cross-sectional study that included 120 patients with papillary thyroid cancer treated at the hospital and 120 healthy volunteers selected as the control group who underwent physical examination. The relative expression levels of microRNA-221 and microRNA-451 were compared between the thyroid papillary carcinoma group (prior to treatment) and the control group. Additionally, microRNA-221 and microRNA-451 expression levels were analyzed in patients with papillary thyroid carcinoma across different pathological characteristics.
Results. Serum microRNA-221 relative levels were significantly higher (p<0.001) in the papillary carcinoma group compared to the control group, while microRNA-451 levels were higher in the control group (p<0.001). In the papillary carcinoma group, microRNA-221 expression was significantly higher in patients with extracapsular invasion (p<0.001), lymphatic metastasis (p=0.003), and poor prognosis (p<0.001). Conversely, microRNA-451 expression was significantly lower (p<0.001) in patients with extracapsular invasion, lymphatic metastasis and poor prognosis. In the multivariate logistic regression analysis, morphological features suggestive of an aggressive clinical behavior (extracapsular invasion and lymphatic metastasis) were related to high expression of microRNA-221 and low expression of microRNA-451 in patients with thyroid papillary carcinoma (p<0.001).
Conclusions. Serum microRNA-221 and microRNA-451 expression levels are significantly higher and lower, respectively, in patients with papillary thyroid carcinoma, particularly in patients with morphological features suggestive of an aggressive clinical behavior (extracapsular invasion and lymphatic metastasis) and, therefore, of a poor prognosis.
##plugins.generic.usageStats.downloads##
Erreferentziak
FILETTI S, DURANTE C, HARTL D LEBOULLEUX S, LOCATI LD, NEWBOLD K et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2019; 30(12): 1856-1883. https://doi.org/10.1093/annonc/mdz400
MIN Y, HUANG Y, WEI M,WEI, X, CHEN H WANG, X CHEN J et al. Preoperatively predicting the central lymph node metastasis for papillary thyroid cancer patients with Hashimoto's thyroiditis. Front Endocrinol 2021; 12: 713475. https://doi.org/10.3389/fendo.2021.713475
YU J, DENG Y. Lymph node metastasis prediction of papillary thyroid carcinoma based on transfer learning radiomics. Nat Commun 2020; 11(1): 4807. https://doi.org/10.1038/s41467-020-18497-3
MOHR AM, MOTT JL. Overview of microRNA biology. Semin Liver Dis 2015; 35(1): 3-11. https://doi.org/10.1055/s-0034-1397344
SEMPERE LF, AZMI AS. MicroRNA-based diagnostic and therapeutic applications in cancer medicine. Wiley Interdiscip Rev RNA 2021; 12(6): e1662. https://doi.org/10.1002/wrna.1662
CELAKOVSKY P, KOVARIKOVA H, CHROBOK V, MEJZLIK JL, VOSMIKOVA H, CHMELAROVA M et al. microrna deregulation in papillary thyroid cancer and its relationship with BRAF V600E mutation. In vivo 2021; 35(1): 319-323. https://doi.org/10.21873/invivo.12262
DAVEY MG, DAVIES M, LOWERY A, LOWERY AJ, MILLER N, KERIN MJ et al. The role of microRNA as clinical biomarkers for breast cancer surgery and treatment. Int J Mol Sci 2021; 22(15). https://doi.org/10.3390/ijms22158290
IQBAL MA, ARORA S, PRAKASAM G, CALIN GA, SYED MA. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med 2019; 70: 3-20. https://doi.org/10.1016/j.mam.2018.07.003
Sharma PC, Gupta A. MicroRNAs: potential biomarkers for diagnosis and prognosis of different cancers. Transl Cancer Res 2020; 9(9): 5798-5818. https://doi.org/10.21037/tcr-20-1294
KHORDADMEHR M, JIGARI-ASL F, EZZATI H, SHAHBAZI R, DADREDDINI S, DAFAEI S et al. A comprehensive review on miR-451: A promising cancer biomarker with therapeutic potential. J Cell Physiol 2019; 234(12): 21716-21731. https://doi.org/10.1002/jcp.28888
CALIN GA, SEVIGNANI C, DUMITRU CD, CROCE CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101(9): 2999-3004. https://doi.org/10.1073/pnas.0307323101
KANEMARU H, FUKUSHIMA S, YAMASHITA J, HONDA N, OYAMA R, KAKIMOTO A et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 2011; 61(3): 187-193. https://doi.org/10.1016/j.jdermsci.2010.12.010
LIANG L, ZHENG X, HU M,CUI Y, ZHONG Q, WANG S et al. MicroRNA-221/222 in thyroid cancer: A meta-analysis. Clin Chim Acta 2018; 484: 284-292. https://doi.org/10.1016/j.cca.2018.06.012
GYORKI DE, UNTCH B, TUTTLE RM, SHAHA AR. Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence. Ann Surg Onclol 2013; 20(7): 2285-2289. https://doi.org/10.1245/s10434-013-2897-6
SURESH R, SETHI S, ALI S, GIORGADZE T, SARKAR FH. Differential expression of microRNAs in papillary thyroid carcinoma and their role in racial disparity. J Cancer Sci Ther 2015; 7(5): 145-154. https://doi.org/10.4172/1948-5956.1000340
DI PAOLO D, PONTIS F, MORO M,CENTONZE G, BERTOLINI G, MILIONE M et al. Cotargeting of miR-126-3p and miR-221-3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling. Mol Oncol 2021; 15(11): 2969-2988. https://doi.org/10.1002/1878-0261.13036
YIP L, KELLY L, SHUAI Y, ARMSTRONG MJ, NIKIFOROV Y, CARTY SE et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 2011; 18(7): 2035-2041. https://doi.org/10.1245/s10434-011-1733-0
BAI H, WU S. miR-451: A novel biomarker and potential therapeutic target for cancer. Onco Targets Ther 2019; 12: 11069-11082. https://doi.org/10.2147/OTT.S230963
LIU N, JIANG N, GUO R, JIANG W, HE Q, XU Y et al. MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol Cancer 2013; 12(1): 123. https://doi.org/10.1186/1476-4598-12-123
GODLEWSKI J, BRONISZ A, NOWICKI M O, CHIOCCA A, LAWLER S. microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell cycle (Georgetown, Tex) 2010; 9(14): 2742-2748
KIM Y, ROH S, LAWLER S FRIEDMAN A. miR451 and AMPK mutual antagonism in glioma cell migration and proliferation: a mathematical model. PloS one 2011; 6(12): e28293. https://doi.org/10.1371/journal.pone.0028293
WANG Z, ZHANG H, ZHANG P, LI J, SHAN Z TENG W. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol 2013; 30(2): 577. https://doi.org/10.1007/s12032-013-0577-9
##submission.downloads##
Argitaratuta
##submission.howToCite##
Zenbakia
Atala
##submission.license##
##submission.license.cc.by-sa4.footer##La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
